The California Institute for Regenerative Medicine, the world’s largest institute dedicated to regenerative medicine, announced its approval of a new program called ReMIND at the September Independent Citizens Oversight Committee (ICOC) meeting that will eventually award up to $110 million to advance basic research in neuropsychiatric diseases—one of the largest investments of its kind in California.
ReMIND ( Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) is a new program designed to accelerate research innovations that would improve the understanding of the biology of neuropsychiatric diseases using stem cell or genetic research as its primary approach. The program includes two distinct and separate funding opportunities: the first, ReMIND-L supports large collaborative multidisciplinary projects, and the second, ReMIND-X supports exploratory, high risk, high reward projects. The program will fund research at academic, non-profit, and for-profit organizations in California from 2024 to 2028.